Abstract We have designed a rapid and convenient strategy to determine nine of the most common mutations in the 21-hydroxylase gene (CYP21). The frequency of the mutations was investigated in 34 Japanese patients affected with congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency. We characterized 82% of the CAH chromosomes. The most frequent mutations were a C/A to G substitution in intron 2 in the salt-wasting form of the disease and an I172N in the simple virilizing form. Three de novo mutations were found. Two homozygous mutations (S268T and N493S) were detected by direct sequencing of all exons of CYP21 in two siblings, who had a normal genotype at all positions screened. We successfully applied these methods for prenatal diagnosis in one family. These procedures proved to be sensitive and rapid for the detection of the most common known mutations in the CYP21 gene and may be useful for genetic screening.
Introduction
Congenital adrenal hyperplasia (CAH; MIM *201910) is one of the most common forms of inborn errors of metabolism. Steroid 21-hydroxylase (21-OH) deficiency is a cortisol biosynthesis autosomal recessive disorder that accounts for 90%-95% of CAH cases. A wide spectrum of clinical variants exists, from severe or classical forms, which are evident at birth, to mild, late-onset nonclassical forms. Severe forms include two groups of patients: those with a complete lack of 21-OH function (salt-wasting, SW), and those with partial impairment of 21-OH (simple virilizing, SV) (White et al. 1987) .
The affected enzyme, 21-OH, is encoded by an active gene, CYP21, located on the short arm of chromosome 6, with an adjacent inactive pseudogene (CYP21P). Many mutations responsible for the disease have been described (Rodrigues et al. 1987; Higashi et al. 1988b Higashi et al. , 1991 Wu and Chung 1991) . Most of these mutations are results of gene conversion events between the functional CYP21 gene and the pseudogene (CYP21P) acting as a reservoir of mutations (Higashi et al. 1988a) . Approximately 90% of the cases are caused by nine specific point mutations and deletions in the CYP21 gene: P30L, 655C/AϾ G in intron 2 (i2g), del 8-bp in exon 3, I172N, triple substitution in exon 6 (E6 cluster), V281L, 1761insT, Q318X, and R356W. We designed rapid and convenient PCR-based methods to screen for these known mutations in the CYP21 gene and characterized 34 Japanese patients with 21-OH deficiency.
Materials and methods

Patients
Thirty-four Japanese CAH patients, including three siblings, were studied. There was no consanguinity between the parents of these patients. In 18 families (20 patients), DNA samples from the parents also were analyzed. Twenty-six patients suffered from the salt-wasting (SW) form of the disease and 8 from the simple virilizing (SV) form. No patient was classified as having the nonclassical form. The patients were diagnosed on the basis of an elevated plasma 17-hydroxyprogesterone. CAH with SW was characterized by the onset of hyperkalemia, hyponatremia, dehydration, and shock requiring treatment with both mineralocorticoids and glucocorticoids. The SV form was identified by the presence of ambiguous genitalia in females.
After informed consent was obtained from the patients and/or their parents, genomic DNA was prepared from their peripheral blood leukocytes.
PCR amplification and digestion of PCR products
Polymerase chain reaction (PCR) amplification reactions were carried out in 50-µl reaction mixtures containing 50 mM KCl, 10mM TRIS-HCl, pH 8.3, 1.5 mM MgCl 2 , 0.01% (W/V) gelatin, 200 µM of each dNTP, 1 µM of each nucleotide primer, 1 µg of genomic DNA, and 2.5 units Taq DNA polymerase (TaKaRa, Kyoto, Japan). The PCR products were digested with appropriate restriction enzymes (New England Biolabs, Beverly, MA, USA) according to the manufacturer's protocol.
Detection of CYP21 gene deletions
Deletion of the CYP21 gene was detected by means of PCR with primers 1 and 5 (Table 1 ) and subsequent digestion with TaqI restriction enzyme (Ogawa et al. 1993) . Although the PCR products (210 bp) could be a mixture of both CYP21 and CYP21P sequences, a TaqI restriction site is present only in CYP21P (Fig. 1) . Therefore, in normal subjects, equal-intensity 210-and 187-bp bands could be detected. If one of the CYP21 genes was deleted, the intensity of the 210-bp band decreased relative to that of the 187-bp band. If both the CYP21 genes were deleted, only the 187-bp band could be detected.
Amplification of the CYP21 gene Genomic DNA was amplified in two segments by PCR with primers 1 and 2 (fragment 1) and 3 and 4 (fragment 2), which selectively amplify the CYP21 gene (Table 1) . Primers 2 and 3 were specific for sequences in the nonpseudogene DNA (Tajima et al. 1993b) . Fragment 1 represented a 952-bp segment extending from exon 1 to exon 3. Fragment 2 was 2070 -bp and extended from exon 3 to beyond exon 10. Thirty cycles of amplification were used, each consisting of denaturation for 30s at 94°C, annealing for 30 s at 60°C (primer 1/2) or 64°C (primer 3/4), and extension for 30s (primer 1/2) or 120 s (primer 3/4) at 72°C. If the sample had the CYP21 deletion or an 8-bp deletion in exon 3 (del 8-bp), no PCR products were generated with these primers.
Detection of seven point mutations
For the second round of PCR, 1µl of the PCR product from each first-stage amplification was used with the appropriate primers listed in Table 1 . Thirty cycles of amplification were used, each consisting of a denaturation step for 30s at 94°C, an annealing step for 30s at 58° or 60°C, and an extension step for 30 s at 72°C. Using fragment 1 as a template, we performed a second round of PCR to detect the P30L and i2g mutations. Fragment 2 was used as a template to detect the I172N, E6 cluster, V281L, Q318X, and R356W mutations. The volume of the reaction mixture for PCR was 50 µl and 5µl of each PCR product was incubated for at least 2 h with 5-10 units of the appropriate restriction enzyme. Electrophoresis was performed using a 3%-6% agarose gel and visualized by ethidium bromide staining. Table 1 . PCR primers used for amplification of CYP21 gene
Ϫ42-Ϫ22 5Ј-CTG AGG TGC CAC TTA TAG CTC-3Ј Primer 6 ϩ67-ϩ88 5Ј-AAG CTC CGG AGC CTC CAC CTC G-3Ј Primer 7
ϩ195-ϩ214 5Ј-AGA TCA GCC TCT CAC CTT GC-3Ј Primer 8 ϩ524-ϩ547 5Ј-TGG GGC ATC CCC AAT CCA GGT CCC-3Ј Primer 9
ϩ656-ϩ677 5Ј-ACC AGC TTG TCT GCA GGA GGA T-3Ј Primer 10 ϩ1000-ϩ1020 5Ј-TCT CCG AAG GTG AGG TAA CA T-3Ј Primer 11b
ϩ1375-ϩ1395 5Ј-AGC TGC ATC TCC ACG ATG TGA-3Ј Primer 11a
ϩ1375-ϩ1397 5Ј-TCA GCT GCT TCT CCT CGT TGT GG-3Ј Primer 12
ϩ1373-ϩ1396 5Ј-GAT CAC ATC GTG GAG ATG CAG CTG-3Ј Primer 13 ϩ2129-ϩ2153 5Ј-TGG GCC GTG TGG TGC GGT GGG GCA A-3Ј Primer 14 ϩ1975-ϩ1993 5Ј-CCA GAT TCA GCA GCG ACT G-3Ј Primer 15
ϩ2113-ϩ2136 5Ј-TGG GGC AAG GCT AAG GGC ACA AC C-3Ј
Underlined primers are antisense primers Italic letters indicate modified nucleotides V281L and Q318X mutations Because these mutations abolish restriction enzyme recognition sites, we performed nested PCR using primers 12 and 13, followed by ApaLI or PstI digestion. When the V281L mutation is present, the ApaLI restriction site is lost, and when the Q318X mutation is present, the PstI site is lost. Digestion of the PCR products with ApaLI yielded 375-, 311-, and 95-bp fragments if the V281L mutation was absent, and 686-and 95-bp fragments if the mutation was present. Digestion with PstI yielded 299-, 204-, 158-, and 120-bp fragments if the Q318X mutation was absent, and 457-, 204-, and 120-bp fragments if the mutation was present.
P30L, i2g, I172N, and R356W mutations
We developed a rapid, modified PCR assay using mismatch primers to detect these mutations.
P30L mutation
Using primers 6 and 7, a 148-bp fragment containing the 89C Ͼ T mutation site was amplified. The mismatched G in primer 6 introduced an AccII restriction site in the normal sequence. Digestion of the PCR product with AccII yielded 126-and 22-bp fragments if the mutation was absent and a 148-bp fragment if the mutation was present.
i2g mutation A modified PCR was performed for detection of the 655C/ A Ͼ G mutation using primers 8 and 9. Primer 9 was designed to introduce a Sau3AI restriction site in the mutant PCR products. Digestion of the PCR product yielded a 156-bp fragments if the mutation was absent and 133-and 23-bp fragments if the mutation was present.
I172N mutation
Using primers 3 and 10, we performed nested PCR to detect the 999T Ͼ A mutation. Primer 10 was designed to introduce an NdeI site into the normal products. Digestion of the PCR products with NdeI yielded a 320-bp fragment if the mutation was absent and 297-and 23-bp fragments if the mutation was present.
R356W mutation
A modified PCR amplification was performed to detect the R356W mutation using primers 14 and 15. Primer 15 was designed to introduce an Eco52I restriction site in the normal PCR products. Digestion of the PCR product yielded a 162-bp fragment if the mutation was present and a 136-bp fragment if the mutation was absent.
E6 cluster mutation
E6 cluster mutations were analyzed by means of allelespecific PCR. Two PCRs were performed, one reaction using primers 3 and 11b detected the normal allele, and the other with primers 3 and 11a detected the mutant allele. If the sample was normal and homozygous, then a product would be generated only from the reaction containing the normal primer. Conversely, if the sample was homozygous mutant, a product would be generated only from the reaction containing the mutant primer. If, however, the sample was heterozygous, products would be generated from both the normal and mutant reactions (Wilson et al. 1995) .
1761insT mutation When none of the seven mutations or deletions could account for one of the diseased alleles, we sequenced exon 7 of the CYP21 gene from the patient to determine whether there was an insertion of T at nucleotide 1761 (1761insT).
Direct sequencing
Patients 29 and 30 (siblings) were screened for the most common known mutations, but none of these mutations were detected. We further analyzed these patients by direct sequencing of all the exons of the CYP21 gene. The primers used to amplify each exon of CYP21 are listed in Table 2 . For the amplification of exon 3, the first stage of PCR was performed using primers 8 and 11b (specific for the active gene). All nested PCR products were directly sequenced on a Pharmacia LKB A.L.F. DNA Sequencer (Uppsala, Sweden) using a Thermo-Sequenase cycle sequencing kit (Amersham, Buckingham Shire, UK).
Prenatal diagnosis
Prenatal diagnosis was requested from the family of patient 15, who was homozygous for the i2g mutation. After obtaining informed consent, whole blood was collected from her parents and sister. Chorionic villus sampling was performed at 12 weeks gestation. DNA was extracted by a standard procedure and analyzed by a modified PCR as described in Materials and methods.
Results
The distribution of the mutations detected in CYP21 is shown in Table 3 . Among the 68 chromosomes, 56 (82%) were characterized by screening for the seven most common point mutations and deletions. Both chromosomes were affected by one of these mutations in 25 (73%) patients, 6 (18%) patients had only one copy of one of these mutations, and 3 (9%) patients harbored none of the tested mutations. The most frequent mutations were i2g (26%), R356W (18%), a deletion of the CYP21 gene (12%), I172N (12%), and Q318X (9%). The P30L, E6 cluster, and 1761insT mutations were rare, and the del 8-bp in exon 3 was not detected in this study. The distribution of the mutation frequencies in Japanese populations does not differ significantly from those previously reported (Speiser et al. 1992) , except for the frequency of the deletion of the CYP21 gene. The frequency of a deletion of the CYP21 gene in Japan is lower than in Western countries (20%-30%) (Wilson et al. 1995; Speiser et al. 1992; Wedell et al. 1994) . Two families in this series had one allele with more than one mutation. Patient 19 had the I172N and R356W mutations on his maternal allele while patient 21 carried the V281L, 1761insT, and Q318X mutations on her paternal allele. These complex alleles probably resulted from large gene conversions or multiple mutation events. Analysis of the segregation of point mutations and deletions in the 18 CAH pedigrees (20 patients) showed three de novo mutations (8% allelic frequency; an i2g mutation in patient 17, a P30L in patient 31, and an R356W in patient 33). The de novo mutation rate for this disease is reportedly low (Ͻ1%) (Wedell et al. 1994; Barbat et al. 1995; , although it has been reported to be higher in Japanese populations (~20%) (Tajima et al. 1993a,b) . Our result supports the conclusion that the incidence of de novo mutations among Japanese is high.
Direct sequencing of CYP21 in patients 29 and 30 revealed homozygous S268T and N493S mutations (Fig. 2) . Their parents were heterozygous for these two mutations. The S268T mutation has been reported to be a normal polymorphism (Rodrigues et al. 1987; Wu and Chung 1991) , although the functional effect of the N493S mutation has never been analyzed. Barbat et al. (1995) described the N493S mutation as a disease-causing mutation, but Wedell and Luthman (1993) considered this change to be normal polymorphism. Ordonez-Sánchez et al. (1998) found a very high frequency of the N493S mutation in a Mexican population, and the proportion of homozygosity for the N493S substitution was higher for patients. Rodrigues et al. (1987) also reported a patient in whom a hemizygous N493S mutation was combined with the S268T mutation. It is possible that the N493S substitution may result in decreased enzymatic activity only when combined with the effect of the S268T mutation, and that these two changes appear in linkage disequilibrium. A synergistic effect of partially inacti- Primer rev-1 Ϫ45-Ϫ26 5Ј-CTT GAG CTA TAA GTG GCA CC-3Ј Primer KS-2 ϩ244-ϩ261 5Ј-ACC CTC TCC GTC ACC TCC-3Ј Exon 2
Primer rev-3 ϩ257-ϩ274 5Ј-AGG GTC CTC TCT CCG CTG-5Ј Primer KS-4 ϩ452-ϩ470 5Ј-TAA GAC CAG CCT GGG CAA C-3Ј Exon 3
Primer rev-5 ϩ605-ϩ624 5Ј-GAA GGT CAG GCC CTC AGC TG-3Ј Primer KS-6 ϩ853-ϩ873 5Ј-TAC TGT GAG AGG CGA GGC TGA-3Ј Exon 4-5
Primer rev-7 ϩ890-ϩ907 5Ј-TGC ACA GCG GCC TGC TGA-5Ј Primer KS-8 ϩ1239-ϩ1257 5Ј-CCT ACA ACC CAG GGG TGT C-3Ј Exon 6
Primer rev-9 ϩ1270-ϩ1288 5Ј-GTG GAG GGA GAG GCT CCT T-3Ј Primer KS-10 ϩ1471-ϩ1490 5Ј-AGA ACC CGC CTC ATA GCA AT-3Ј Exon 7
Primer rev-11 ϩ1520-ϩ1540 5Ј-CAC TCT CTA CTC CTC TCC CCA-3Ј Primer KS-12 ϩ1808-ϩ1825 5Ј-TGG CCA GGT TGC TGG GAA-3Ј Exon 8
Primer rev-13 ϩ1923-ϩ1940 5Ј-TGG AGG CTG GGC AGC TGT-3Ј Primer KS-14 ϩ2211-ϩ2229 5Ј-TGG AGT TAG AGG CTG GCC A-3Ј Exon 9
Primer rev-15 ϩ2177-ϩ2196 5Ј-GAT GAG TGA GGA AAG CCC GA-3Ј Primer KS-16 ϩ2374-ϩ2391 5Ј-ACC AGC CTC CAC CAC ATT-3Ј Exon 10
Primer rev-17 ϩ2701-ϩ2721 5Ј-TGA ACG CCT CCC CAC CCA-3Ј Primer KS-18 ϩ2749-ϩ2770 5Ј-AGG GGT TCG TAC GGG AGC AAT A-3Ј
Antisense primers are underlined vating mutations has already been documented for the CYP21 gene (Nikoshkov et al. 1997) .
The DNA analysis of a fetus from family 15 revealed that only one of the chromosome 6 alleles carried the i2g mutation (Fig. 3) , predicting that the fetus would be unaffected. After delivery, this prediction was confirmed by postnatal DNA analysis and hormonal studies.
Discussion
We have designed a coordinated strategy to detect the nine most common 21-hydroxylase mutations. Depending upon the mutation to be detected, we applied one of two simple strategies: digestion of PCR-amplified gene fragments with appropriate restriction enzymes or the use of modified PCR methods employing mismatch primers followed by restriction analysis. In contrast to previous methods, such as dot blot analysis, single-strand conformation polymorphism (using radioactive probes), or allele-specific PCR (which amplifies normal and mutant alleles in different tubes) (Speiser et al. 1992; Ogawa et al. 1993; Tajima et al. 1993b; Wilson et al. 1995) , this strategy could characterize six common CYP21 gene mutations (P30L, i2g, I172N , V281L, Q318X, and R356W) by using ethidium bromide-stained agarose gel and six common restriction enzymes. Because we could not develop a modified PCR approach for the E6 cluster mutation, we applied allele-specific PCR to detect this mutation. Using these rapid and convenient PCR-based methods, we successfully screened 34 CAH patients. Our results indicate that most (76%; 52/68) of the CAH mutations may be detected by screening for five mutations (i2g, I172N, Q318X, R356W, and deletion of CYP21).
The most frequent mutations found in the SW form of the disease were i2g (29% of the SW chromosomes), R356W (17%), deletion (13%), and Q318X (11%). In the SV form, I172N was very frequent (37% of the SV chromosomes). Phenotype-genotype correlations may be drawn by considering the phenotype of patients homozygous or hemizygous for these mutations (Table 4) . Individuals homozygous or hemizygous for i2g, the E6 cluster, Q318X, and R356W had an SW phenotype, suggesting that these mutations were responsible for the SW phenotype. Conversely, those who were homozygous or hemizygous for the I172N mutation had an SV phenotype. However, the phenotypes of the patients who were compound heterozygotes could not be predicted from their genotypes with complete certainty. For instance, patients whose genotypes were i2g/R356W could have either the SV or SW phenotype (see Table 4 ).
Patient 9, who was clinically diagnosed as having SW, had an affected younger brother (patient 10) who had not developed salt-losing symptoms. Similarly, patient 7, who did not have SW, had a younger sister (not shown in Table  4 ) who died of hypovolemic shock. Indeed, the mutation i2g, which leads to aberrant splicing, was found in both clinical forms. This may be explained by differences in the rate of correct splicing in the adrenals of the patients White et al. 1994) . It is also possible that the phenotype may depend on individual variations, a term that must include not only other genetic factors but also nongenetic factors such as environmental stress.
Since the introduction of neonatal screening for CAH, most children are diagnosed before salt-wasting symptoms develop (Pang et al. 1988) . We have found that genotyping is a very useful tool for predicting disease severity in CAH patients. However, caution is needed when analyzing the CYP21 genes to avoid misinterpretation of the genotype data because the CYP21 gene in patients with CAH may have undergone considerable variations in the gene arrangement as well as in the number of point mutations.
With proper vigilance, however, a rapid and accurate diagnosis of CAH can be made by typing the CYP21 mutations.
In conclusion, PCR-based screening methods are useful in genotyping the Japanese 21-OH-deficient population. Our results showed a close, but not complete, correlation between the molecular defect and the clinical expression of this disease. Therefore, the methods described here are suitable for genetic screening, including the prenatal diagnosis of disease.
